We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

On February 3 rd, the company announced that it had completed its acquisition of Ambry Genetics, a genetic testing company that strives to improve health by understanding the relationship between ...

Shares of Tempus AI , Inc. (NASDAQ:TEM) climbed 5% in pre-open trading Tuesday following the completion of its acquisition of ...

Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.

We recently compiled a list of the 10 Firms Shine Amid Market Slump. In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against the other stocks. Ten companies ...

Tempus AI Inc. (NASDAQ:TEM) grew its share prices by 7.23 percent on Monday to end at $61.54 apiece as investor sentiment was fueled by news that it completed the acquisition of Ambry Genetics ...

Let's explore the Tempus AI stock price and whether it is a good company to buy and hold despite its overvaluation.

Highlights,Acquisition Deal Finalized:,Tempus AI acquired,Ambry Genetics,for,$600 million,in cash and stock.,Strategic ...